156 related articles for article (PubMed ID: 38730287)
21. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
[TBL] [Abstract][Full Text] [Related]
22. Relationship between
Bu L; Tu N; Wang K; Zhou Y; Xie X; Han X; Lin H; Feng H
Korean J Radiol; 2022 Jan; 23(1):112-123. PubMed ID: 34983098
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer.
Nakanishi K; Nakamura S; Sugiyama T; Kadomatsu Y; Ueno H; Goto M; Ozeki N; Fukui T; Iwano S; Chen-Yoshikawa TF
BMC Cancer; 2021 Sep; 21(1):983. PubMed ID: 34474680
[TBL] [Abstract][Full Text] [Related]
24. Effect of Epidermal Growth Factor Receptor Mutation on Positron Emission Tomography/Computed Tomography in Lung Cancer.
Park JS; Park HY; Choi Y
Anticancer Res; 2024 Jun; 44(6):2681-2687. PubMed ID: 38821597
[TBL] [Abstract][Full Text] [Related]
25. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma.
Huang CT; Yen RF; Cheng MF; Hsu YC; Wei PF; Tsai YJ; Tsai MF; Shih JY; Yang CH; Yang PC
Med Oncol; 2010 Mar; 27(1):9-15. PubMed ID: 19130320
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of
Zhang Y; Han J; Li J; Cao J; Zhou Y; Deng S; Zhang B; Yang Y
J Cancer Res Clin Oncol; 2024 May; 150(5):265. PubMed ID: 38769201
[TBL] [Abstract][Full Text] [Related]
27. Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma.
Takamochi K; Mogushi K; Kawaji H; Imashimizu K; Fukui M; Oh S; Itoh M; Hayashizaki Y; Ko W; Akeboshi M; Suzuki K
PLoS One; 2017; 12(4):e0175622. PubMed ID: 28422979
[TBL] [Abstract][Full Text] [Related]
28. Can
Du B; Wang S; Cui Y; Liu G; Li X; Li Y
BMJ Open; 2021 Jun; 11(6):e044313. PubMed ID: 34103313
[TBL] [Abstract][Full Text] [Related]
29. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on
Takada K; Toyokawa G; Okamoto T; Baba S; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Honda H; Oda Y; Maehara Y
Cancer Med; 2017 Nov; 6(11):2552-2561. PubMed ID: 28980429
[TBL] [Abstract][Full Text] [Related]
30. Patlak-Ki derived from ultra-high sensitivity dynamic total body [
Wang D; Qiu B; Liu Q; Xia L; Liu S; Zheng C; Liu H; Mo Y; Zhang X; Hu Y; Zheng S; Zhou Y; Fu J; Chen N; Liu F; Zhou R; Guo J; Fan W; Liu H
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3400-3413. PubMed ID: 37310427
[TBL] [Abstract][Full Text] [Related]
31. Quantitative parameters of static imaging and fast kinetics imaging in
Meng N; Zhang M; Ren J; Fu F; Xie B; Wu Y; Li Z; Dai B; Li Y; Feng T; Xu T; Wang M
Quant Imaging Med Surg; 2023 Sep; 13(9):5579-5592. PubMed ID: 37711783
[TBL] [Abstract][Full Text] [Related]
32. Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor mutation.
Lee EY; Khong PL; Lee VH; Qian W; Yu X; Wong MP
Clin Nucl Med; 2015 Mar; 40(3):e190-5. PubMed ID: 25608155
[TBL] [Abstract][Full Text] [Related]
33. 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.
Guan J; Xiao NJ; Chen M; Zhou WL; Zhang YW; Wang S; Dai YM; Li L; Zhang Y; Li QY; Li XZ; Yang M; Wu HB; Chen LH; Liu LY
Medicine (Baltimore); 2016 Jul; 95(30):e4421. PubMed ID: 27472739
[TBL] [Abstract][Full Text] [Related]
34. Correlation of 18F-fluorodeoxyglucose uptake on positron emission tomography with Ki-67 index and pathological invasive area in lung adenocarcinomas 30 mm or less in size.
Murakami S; Saito H; Sakuma Y; Mizutani Y; Ishikawa Y; Kondou T; Oshita F; Yokose T; Kameda Y; Suga Y; Ito H; Tsuboi M; Nakayama H; Noda K; Yamada K
Eur J Radiol; 2010 Aug; 75(2):e62-6. PubMed ID: 20005653
[TBL] [Abstract][Full Text] [Related]
35. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
36. Clinical feasibility study of early 30-minute dynamic FDG-PET scanning protocol for patients with lung lesions.
Du F; Wumener X; Zhang Y; Zhang M; Zhao J; Zhou J; Li Y; Huang B; Wu R; Xia Z; Yao Z; Sun T; Liang Y
EJNMMI Phys; 2024 Mar; 11(1):23. PubMed ID: 38441830
[TBL] [Abstract][Full Text] [Related]
37. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
[TBL] [Abstract][Full Text] [Related]
38. [The value of (18)F-FDG PET-CT imaging in predicting the malignant potential of GIST].
Li SX; Tang MD; Lin DY; Liu DJ; Lyu QH; Zhang JP; Cai ZH
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):821-827. PubMed ID: 29151288
[No Abstract] [Full Text] [Related]
39. Improving diagnostic performance of
Yang DD; Mirvis E; Goldring J; Patel ARC; Wagner T
Clin Radiol; 2019 Oct; 74(10):818.e17-818.e23. PubMed ID: 31420186
[TBL] [Abstract][Full Text] [Related]
40. The diagnostic and predictive efficacy of
Guo Y; Zhu H; Yao Z; Liu F; Yang D
Eur J Radiol; 2021 Aug; 141():109792. PubMed ID: 34062472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]